Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41401-021-00735-z http://scihub22266oqcxt.onion/10.1038/s41401-021-00735-z 34349236!8334341!34349236     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34349236&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Acta+Pharmacol+Sin 2022 ; 43 (4): 788-796 Nephropedia Template TP {{tp|p=34349236|t=2022. Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein |pdf=|usr=}}{{34349236}} gab.com Text Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein JO: Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=34349236 #FOAvip An epidemic of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading worldwide. SARS-CoV-2 relies on its spike protein to invade host cells by interacting with the human receptor protein Angiotensin-Converting Enzymes 2 (ACE2). Therefore, designing an antibody or small-molecular entry blockers is of great significance for virus prevention and treatment. This study identified five potential small molecular anti-virus blockers via targeting SARS-CoV-2 spike protein by combining in silico technologies with in vitro experimental methods. The five molecules were natural products that binding to the RBD domain of SARS-CoV-2 was qualitatively and quantitively validated by both native Mass Spectrometry (MS) and Surface Plasmon Resonance (SPR). Anti-viral activity assays showed that the optimal molecule, H69C2, had a strong binding affinity (dissociation constant K(D)) of 0.0947 microM and anti-virus IC(50) of 85.75 microM. Twit Text FOAVip Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein ????Acta Pharmacol Sin http://www.kidney.de/pget.php?&tw=1&pmid=34349236 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34349236 #FOAvip English Wikipedia <ref>{{Cite pmid|34349236}}</ref> Discovery of potential small molecular SARS-CoV-2 entry blockers targeting the spike protein #MMPMID34349236 Wang L; Wu Y; Yao S; Ge H; Zhu Y; Chen K; Chen WZ; Zhang Y; Zhu W; Wang HY; Guo Y; Ma PX; Ren PX; Zhang XL; Li HQ; Ali MA; Xu WQ; Jiang HL; Zhang LK; Zhu LL; Ye Y; Shang WJ; Bai F Acta Pharmacol Sin 2022[Apr]; 43 (4): 788-796 PMID34349236show ga An epidemic of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading worldwide. SARS-CoV-2 relies on its spike protein to invade host cells by interacting with the human receptor protein Angiotensin-Converting Enzymes 2 (ACE2). Therefore, designing an antibody or small-molecular entry blockers is of great significance for virus prevention and treatment. This study identified five potential small molecular anti-virus blockers via targeting SARS-CoV-2 spike protein by combining in silico technologies with in vitro experimental methods. The five molecules were natural products that binding to the RBD domain of SARS-CoV-2 was qualitatively and quantitively validated by both native Mass Spectrometry (MS) and Surface Plasmon Resonance (SPR). Anti-viral activity assays showed that the optimal molecule, H69C2, had a strong binding affinity (dissociation constant K(D)) of 0.0947 microM and anti-virus IC(50) of 85.75 microM. |*COVID-19 Drug Treatment[MESH] |*Spike Glycoprotein, Coronavirus[MESH] |Humans[MESH] |Protein Binding[MESH]Discovery of potential small molecular SARS-CoV-2 entry blockers targe(epmc).pdf DeepDyve Pubget Overpricing